LPL Financial
ESPR

LPL Financial’s Esperion Therapeutics ESPR Stock Holding History

LPL Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.4K Sell
29,228
-263,039
-90% -$736K ﹤0.01% 5931
2026
Q1 		$801K Buy
292,267
+262,957
+897% +$832K ﹤0.01% 4368
2025
Q4 		$108K Buy
29,310
+1,676
+6% +$5.42K ﹤0.01% 5580
2025
Q3 		$73.2K Buy
+27,634
New +$53.4K ﹤0.01% 5574
2024
Q4 		– Sell
-13,548
Closed -$22.4K – 5333
2024
Q3 		$22.4K Sell
13,548
-4,000
-23% -$8.08K ﹤0.01% 5072
2024
Q2 		$39K Buy
+17,548
New +$41.3K ﹤0.01% 4870

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

LPL Financial's ESPR Position: Q2 2026 in Review

LPL Financial reduced its Esperion Therapeutics (ESPR) stake by 90% in Q2 2026, selling an estimated $736K and leaving 29,228 shares worth $92.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5931.

LPL Financial first reported a position in ESPR in Q2 2024 and has held it in 6 quarters since. The position peaked at $801K in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • LPL Financial held 29,228 shares of Esperion Therapeutics worth $92.4K as of Q2 2026.
  • LPL Financial sold 263,039 Esperion Therapeutics shares in Q2 2026, an estimated $736K.
  • Esperion Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5931 holding.
  • LPL Financial first reported a position in Esperion Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • LPL Financial's Esperion Therapeutics position peaked at $801K in Q1 2026.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.